Dr. Nishant M. Bhensdadia, MD

Dr. Bhensdadia practices at US Renal Care Sarasota Dialysis - HOPD in Sarasota, Florida.

Dr. Bhensdadia's NPI, 1801057096, was assigned on June 19, 2008. Dr. Bhensdadia graduated from M.P. Shah Medical College in 2005. Dr. Bhensdadia holds Florida license ME119186.

Dr. Bhensdadia's primary practice is US Renal Care Sarasota Dialysis - HOPD, at 1921 Waldemere St, Sarasota, FL 34239.

Dr. Bhensdadia's primary practice is US Renal Care Sarasota Dialysis - HOPD in Sarasota, Florida. Dr. Bhensdadia is also affiliated with Sarasota Memorial Hospital - Sarasota Campus. The medical group on file is Florida Kidney Physicians. Dmand AI also links Dr. Bhensdadia to 3 more hospitals, 4 dialysis centers, 2 group practices and clinics and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Bhensdadia practices, 11 sites in all. Vendor and product names are available with a free account.

Nephrology is Dr. Bhensdadia's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Bhensdadia is board certified in internal medicine by the American Board of Internal Medicine. Dmand AI has Dr. Bhensdadia's licenses on file in 4 states: Florida, South Carolina, Illinois and North Carolina.

Dmand AI lists acute kidney failure, chronic kidney disease, fluid and electrolyte imbalances, kidney cysts and parathyroid gland disorder among the conditions Dr. Bhensdadia treats.

CMS data shows 3,305 Medicare services from Dr. Bhensdadia across 19 procedure codes in 2024, for 751 Medicare patients. Medicare paid $281,766 for them.

CMS counts 751 Medicare patients who saw Dr. Bhensdadia in 2024. The largest group is 75 to 84, with 329 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 11% are also on Medicaid. Their average risk score is 3.43, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Bhensdadia's median patient age at 78, with 38% women.

In 2024, Dr. Bhensdadia wrote 3,259 Medicare Part D claims for 479 patients. 79% of them were for generic drugs. CMS names the drug for 3,017 of them, across 42 drugs with 11 or more claims each, at $891,831 in total drug cost. In 2023, CMS named 2,382 claims across 43 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Bhensdadia for performance year 2024, reported individually. Dr. Bhensdadia accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 2 papers to Dr. Bhensdadia in 2013. The most frequent topics are Creatinine. Dr. Bhensdadia's most frequent co-authors are Joseph L. Alge, MD, John M. Arthur, MD and Maria F. Lopes-Virella, MD.

CMS Open Payments shows 72 general payments to Dr. Bhensdadia from 26 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 90% of the total. Sanofi and Genzyme US Companies paid the most, $272.

Dmand AI lists 5 awards for Dr. Bhensdadia, most recently Award for Research Presentation in 2013.

Dr. Bhensdadia graduated from M.P. Shah Medical College in 2005. Dr. Bhensdadia is a member of ASN.

Dr. Bhensdadia is in network with 19 carriers, including Elevance, Aetna and Excellus BlueCross BlueShield. Medicare plans come from the most carriers, 12. Check the plan with the practice before a visit.